Neurodegenerative Disease, Cancer Stocks Among Top Biotech Gainers In 2021

Benzinga2021-07-05

Biotech stocks underperformed the broader market in the first half of 2021, with the iShares Nasdaq Biotechnology ETF advancing about 8% year-to-date compared to the roughly 14% gain for the S&P 500 ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment（6）

CelesteK
·2021-07-06
??
Reply
Like
Report
CelesteK
·2021-07-06
??
Reply
Like
Report
Investcub
·2021-07-06
The rise of the biotechs
Reply
1
Report
GoLUCK
·2021-07-05
Nice
Reply
1
Report
Tigal80
·2021-07-05
like
Reply
1
Report
Fold Replies
- 钱来多多:
  Hi
  2021-07-06
  Reply
  Report
Geminifx
·2021-07-05
Good read
Reply
3
Report
Fold Replies
- Tigal80:
  yes
  2021-07-05
  Reply
  Report

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/1111176344?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2021-07-05 13:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1111176344","market":"us","top_or_hot":-1,"title":"Neurodegenerative Disease, Cancer Stocks Among Top Biotech Gainers In 2021","media":"Benzinga","content":"<div>\n<p>Biotech stocks underperformed the broader market in the first half of 2021, with the iShares Nasdaq Biotechnology ETF advancing about 8% year-to-date compared to the roughly 14% gain for the S&P 500 ...</p>\n\n<a href=\"https://www.benzinga.com/general/biotech/21/07/21773695/neurodegenerative-disease-cancer-stocks-among-top-biotech-gainers-in-2021\">Source Link</a>\n\n</div>\n","source":"lsy1606299360108","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Neurodegenerative Disease, Cancer Stocks Among Top Biotech Gainers In 2021</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNeurodegenerative Disease, Cancer Stocks Among Top Biotech Gainers In 2021\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-05 13:43 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/general/biotech/21/07/21773695/neurodegenerative-disease-cancer-stocks-among-top-biotech-gainers-in-2021><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Biotech stocks underperformed the broader market in the first half of 2021, with the iShares Nasdaq Biotechnology ETF advancing about 8% year-to-date compared to the roughly 14% gain for the S&P 500 ...</p>\n\n<a href=\"https://www.benzinga.com/general/biotech/21/07/21773695/neurodegenerative-disease-cancer-stocks-among-top-biotech-gainers-in-2021\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ANVS","symbol_name":"Annovis Bio, Inc.","start_time":0,"source_url":"https://www.benzinga.com/general/biotech/21/07/21773695/neurodegenerative-disease-cancer-stocks-among-top-biotech-gainers-in-2021","article_id":"1111176344","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1111176344","pubTimestamp":1625463785,"columns":[],"sourceInfo":{"source_id":"lsy1606299360108","name":"Benzinga"},"weMediaInfo":null,"summary":"Biotech stocks underperformed the broader market in the first half of 2021, with the iShares Nasdaq ","collect":0,"end_time":0,"defaultTopTitle":"benzinga.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"ANVS":"Annovis Bio, Inc.","AVXL":"Anavex Life Sciences Corp.","ENTX":"Entera Bio Ltd.","MRK":"默沙东","SAVA":"Cassava Sciences Inc","PDSB":"PDS Biotechnology Corporation","ATOS":"Atossa Genetics Inc"},"translate_title":"神经退行性疾病、癌症股在2021年生物技术类股中名列前茅","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ANVS":0.9,"ATOS":0.9,"AVXL":0.9,"BTX":0.9,"ENTX":0.9,"MRK":0.9,"PDSB":0.9,"SAVA":0.9},"content_text":"Biotech stocks underperformed the broader market in the first half of 2021, with the iShares Nasdaq Biotechnology ETF advancing about 8% year-to-date compared to the roughly 14% gain for the S&P 500 Index.\nIn comparison, the IBB was up 13.6% in the first half of 2020. The strength in the space in the last year was primarily due to risk aversion as the pandemic drove investors into defensive plays such as biotechs. Additionally, companies that kickstarted COVID-19 vaccine programs ran up sharply in 2020.\nThe relatively muted performance so far this year may have to do with the return of risk appetite leading to rotation out of the sector. The rally in vaccine stocks also moderated following emergency use authorizations being accorded for three COVID-19 shots.\nHere are a few stocks that stood out with solid gains amid the muted overall sector performance:\nCassava Sciences Inc : Shares of Cassava, a neurodegenerative disease company, spiked in early February on the back of positive results from the interim analysis of data from an open-label study of simufilam, its lead drug candidate for the treatment of Alzheimer's disease.\nIt hit an intraday high of $117.54 on Feb. 4. After pulling back and consolidating, the stock picked up pace in June. By virtue of the strong advance in the year-to-date period, the stock has tacked on about 1,150%.\nAnnovis Bio Inc : This biopharma that focuses on therapies for neurodegenerative diseases has seen its shares surge by over 1, 060% so far this year.\nThe company's lead drug ANVS401 is being evaluated for multiple indications, including Alzheimer's disease and Parkinson's disease. It works by improving axonal transport by inhibiting the neurotoxic proteins that kill nerve cells. A positive Phase 2 readout for the asset in Alzheimer's disease sent the stock soaring in late April.\nAtossa Therapeutics Inc : The Seattle-based biopharma focusing on treatments for breast cancer and COVID-19 has surged up about 770% year-to-date.\nFrom under $1 at the start of year, the stock rallied to a high of $4.90 in early February on the back of positive Phase 2 data for Endoxifen administered between diagnosis and surgery in breast cancer patients. The upward momentum faltered subsequently and the stock pulled back to a low of $1.48 on April 19.\nAtossa recovered from there and the rally picked up steam in June amid the release of positive final Phase 2 data for Endoxifen and inclusion in the Russell 2000 and 3000 indexes.\nEntera Bio Ltd. : The biopharma, which develops orally delivered large molecule therapeutics for use in areas with significant unmet medical need, has seen its shares surge higher by over 460% so far this year.\nThe company's pipeline consists of EB613, which is being evaluated for osteoporosis, and EB612 for hypoparathyroidism.\nEntera Bio shares jumped in early April when it reported positive topline biomarker data for EB613. The stock received a shot in the arm from the positive six-month bone mineral density results from the Phase 2 clinical trial of EB613, which the company reportedlast week.\nPDS Biotechnology Corp : PDS has gained about 450% year-to-date. The company has oncology and infectious disease programs.\nThe gains for the year-to-date period reflected the presentation of data from the Phase 2 combination study with PDS0101 in HPV-associated tumors at the ASCO conference, and also its COVID-19 program.\nAnavex Life Sciences Corp. shares have gained about 430% year-to-date. The company is developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders.\nThe company's lead product candidate blarcamesine (ANAVEX2-73) is being evaluated for multiple indications. The predictive biomarker of response established with SIGMAR1 mRNA expression correlates significantly with responses in primary and secondary clinical efficacy endpoints from the proof-of-concept Phase 2 trial in Parkinson's disease, the company announced.\nBrooklyn ImmunoTherapeutics Inc : This New York-based gene and cell therapy company has clocked gains of about 375% year-to-date.\nThe company is focused on exploring the role cytokine-based therapy can have in treating patients with cancer. The company is also exploring opportunities to advance oncology, blood disorder and monogenic disease therapies using highly innovative gene editing/cell therapy technology.\nBrooklyn initiated a mid-stage study of IRX-2 in combination with Merck & Co., Inc.'s Keytruda and chemotherapy in triple-negative breast cancer.\nIn March, the company completed its reverse merger with NTN Buzztime.\nHoward Federoff took over as CEO in early April. Later that month, the company acquired an exclusive license for mRNA gene editing and cell therapies technology of Factor Bioscience and Novellus Therapeutics, pursuant to an exercise of a previously announced option.\nThe company has also been added to the Russell 3000 Index.\nBrooklyn's most advanced program is the study of the lead asset IRX-2, a human cell-derived biologic with multiple active cytokine components in patients with head and neck cancer. With commercialization years away — and ultimately contingent on IRX-2 clearing clinical and regulatory hurdles — the valuation of Brooklyn looks a little stretched.","kind":"news","is_publish_news":false,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":157638862,"gmtCreate":1625579875256,"gmtModify":1703744256864,"author":{"id":"3580982151771677","authorId":"3580982151771677","name":"CelesteK","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"3580982151771677","authorIdStr":"3580982151771677"},"htmlText":"??","listText":"??","text":"??","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/157638862","repostId":1111176344,"repostType":2,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":157631224,"gmtCreate":1625579850768,"gmtModify":1703744255716,"author":{"id":"3580982151771677","authorId":"3580982151771677","name":"CelesteK","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"3580982151771677","authorIdStr":"3580982151771677"},"htmlText":"??","listText":"??","text":"??","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/157631224","repostId":1111176344,"repostType":2,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":154252882,"gmtCreate":1625531307346,"gmtModify":1703743060540,"author":{"id":"3584582153384625","authorId":"3584582153384625","name":"Investcub","avatar":"https://static.tigerbbs.com/b34bc19b19d991e55d86b53b1e4a44ff","vip":1,"crmLevel":6,"crmLevelSwitch":0,"idStr":"3584582153384625","authorIdStr":"3584582153384625"},"htmlText":"The rise of the biotechs&nbsp;","listText":"The rise of the biotechs&nbsp;","text":"The rise of the biotechs","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/154252882","repostId":1111176344,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":154334836,"gmtCreate":1625478175925,"gmtModify":1703742420400,"author":{"id":"3582022156707091","authorId":"3582022156707091","name":"GoLUCK","avatar":"https://static.tigerbbs.com/59d744194a62c681a6af1d4f6800825b","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3582022156707091","authorIdStr":"3582022156707091"},"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/154334836","repostId":1111176344,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":154935073,"gmtCreate":1625467488492,"gmtModify":1703742282938,"author":{"id":"3575390834397772","authorId":"3575390834397772","name":"Tigal80","avatar":"https://static.tigerbbs.com/86f76710483a16eae0642572ffa5f1be","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3575390834397772","authorIdStr":"3575390834397772"},"htmlText":"like","listText":"like","text":"like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/154935073","repostId":1111176344,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5134952,"gmtCreate":1625555847812,"gmtModify":1663230584337,"authorId":3581580011126880,"author":{"id":3581580011126880,"idStr":"3581580011126880","authorId":3581580011126880,"name":"钱来多多","avatar":"https://static.tigerbbs.com/11ab5676773891c2257d3dc3cdc066ad","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":154935073,"type":1,"supId":0,"prevId":0,"content":"<u>Hi</u>","text":"<u>Hi</u>","html":"<u>Hi</u>"}],"langContent":"EN"},{"id":154072842,"gmtCreate":1625464458386,"gmtModify":1703742238769,"author":{"id":"4087730205940900","authorId":"4087730205940900","name":"Geminifx","avatar":"https://static.tigerbbs.com/15c0fff97ae1992c6604d4f63b930462","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"4087730205940900","authorIdStr":"4087730205940900"},"htmlText":"Good read","listText":"Good read","text":"Good read","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/154072842","repostId":1111176344,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5126434,"gmtCreate":1625467472914,"gmtModify":1663230544829,"authorId":3575390834397772,"author":{"id":3575390834397772,"idStr":"3575390834397772","authorId":3575390834397772,"name":"Tigal80","avatar":"https://static.tigerbbs.com/86f76710483a16eae0642572ffa5f1be","vip":1,"currentWearingBadge":{"badgeId":"44212b71d0be4ec88898348dbe882e03-1","templateUuid":"44212b71d0be4ec88898348dbe882e03","name":"Boss Tiger","description":"The transaction amount of the securities account reaches $100,000","bigImgUrl":"https://static.tigerbbs.com/c8dfc27c1ee0e25db1c93e9d0b641101","smallImgUrl":"https://static.tigerbbs.com/f43908c142f8a33c78f5bdf0e2897488","grayImgUrl":"https://static.tigerbbs.com/82165ff19cb8a786e8919f92acee5213","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.14","exceedPercentage":"60.02%","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1101},"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":154072842,"type":1,"supId":0,"prevId":0,"content":"yes","text":"yes","html":"yes"}],"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":39,"commentSize":6,"repostSize":0,"favoriteSize":1,"likeStatus":false,"favoriteStatus":false}}